Cover Image
市場調查報告書

Altacor Limited:產品平台分析

Altacor Ltd. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 259392
出版日期 內容資訊 英文 26 Pages
訂單完成後即時交付
價格
Back to Top
Altacor Limited:產品平台分析 Altacor Ltd. - Product Pipeline Review - 2014
出版日期: 2014年09月10日 內容資訊: 英文 26 Pages
簡介

Altacor Limited 是開發、製造並商品化治療慢性眼科症狀的稀少藥品之眼科專業企業。該公司的技術活用於乾眼症、眼瞼炎、老化性黃斑部病變、糖尿病視網膜病變、青光眼等疾病的治療藥上。

本報告提供Altacor Limited 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃相關等資訊。

Altacor Ltd.的基本資料

  • Altacor Ltd.概要
  • 主要資訊
  • 企業資料

Altacor Ltd.:R&D概要

  • 主要的治療範圍

Altacor Ltd.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Altacor Ltd.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Altacor Ltd.:藥物簡介

  • ALT-005
  • PRX-00933
  • tranilast
  • ALT-022

Altacor Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Altacor Ltd.:最近的開發平台趨勢

Altacor Ltd.:暫停中的計劃

Altacor Ltd.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06420CDB

Summary

Global Markets Direct's, 'Altacor Ltd. - Product Pipeline Review - 2014', provides an overview of the Altacor Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Altacor Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Altacor Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Altacor Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Altacor Ltd.'s pipeline products

Reasons to buy

  • Evaluate Altacor Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Altacor Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Altacor Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Altacor Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Altacor Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Altacor Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Altacor Ltd. Snapshot
    • Altacor Ltd. Overview
    • Key Information
    • Key Facts
  • Altacor Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Altacor Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Altacor Ltd. - Pipeline Products Glance
    • Altacor Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Altacor Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Altacor Ltd. - Drug Profiles
    • ALT-005
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRX-00933
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tranilast
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALT-022
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Altacor Ltd. - Pipeline Analysis
    • Altacor Ltd. - Pipeline Products by Target
    • Altacor Ltd. - Pipeline Products by Route of Administration
    • Altacor Ltd. - Pipeline Products by Molecule Type
    • Altacor Ltd. - Pipeline Products by Mechanism of Action
  • Altacor Ltd. - Recent Pipeline Updates
  • Altacor Ltd. - Dormant Projects
  • Altacor Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Altacor Ltd., Key Information
  • Altacor Ltd., Key Facts
  • Altacor Ltd. - Pipeline by Indication, 2014
  • Altacor Ltd. - Pipeline by Stage of Development, 2014
  • Altacor Ltd. - Monotherapy Products in Pipeline, 2014
  • Altacor Ltd. - Partnered Products in Pipeline, 2014
  • Altacor Ltd. - Partnered Products/ Combination Treatment Modalities, 2014
  • Altacor Ltd. - Phase III, 2014
  • Altacor Ltd. - Preclinical, 2014
  • Altacor Ltd. - Discovery, 2014
  • Altacor Ltd. - Pipeline by Target, 2014
  • Altacor Ltd. - Pipeline by Route of Administration, 2014
  • Altacor Ltd. - Pipeline by Molecule Type, 2014
  • Altacor Ltd. - Pipeline Products by Mechanism of Action, 2014
  • Altacor Ltd. - Recent Pipeline Updates, 2014
  • Altacor Ltd. - Dormant Developmental Projects,2014

List of Figures

  • Altacor Ltd. - Pipeline by Top 10 Indication, 2014
  • Altacor Ltd. - Pipeline by Stage of Development, 2014
  • Altacor Ltd. - Monotherapy Products in Pipeline, 2014
  • Altacor Ltd. - Partnered Products in Pipeline, 2014
  • Altacor Ltd. - Pipeline by Top 10 Target, 2014
  • Altacor Ltd. - Pipeline by Top 10 Molecule Type, 2014
  • Altacor Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top